Beijing
Genzyme Corp. is planning to construct a new 200,000-sf R&D center in the Zhongguancun Life Science Park in Beijing. The $90 million facility will accommodate research and development in areas including orthopedics, transplant and immune disease, oncology, endocrinology, and cardiovascular disease, as well as laboratory-scale operations for the MACI(R) (matrix-induced autologous chondrocyte implantation) cell therapy and polyclonal antibody operations. LEED certification will be sought for the project, which will include a living roof, a solar thermal system, use of natural light, and low flow water fixtures. The architect is RMJM Hillier with MW Zander as project engineer. Occupancy is slated for 2010.
